PHP25 EXPENDITURES ON DRUGS IN DEVELOPED EUROPEAN COUNTRIES  by Praznovcova, L & Ivanovic, N
A215Abstracts
−4,339,412) and E/P (Beta: −0.16) (p < 0.05 both). Final adjusted
R2: E: 0.937; P/d: 0.918; E/P: 0.906. CONCLUSIONS: trend is
the most signiﬁcant variable in the three models and when an
impact is statistically signiﬁcant, it seems not to present long-
term sustainability because these supply measures have a short-
term impact.
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OBJECTIVE: To distribute the total health spending in Spain for
the years 1980–2000 among the seventeen ICD-9-CM cate-
gories. The study aimed to gather data for 1980, 1985, 1990,
1993, 1996, and 2000 in order to obtain a baseline from which
to analyse the evolution of spending over time. METHODS: The
method used was the top-down approach, starting with overall
spending ﬁgures and, by means of various procedures, breaking
them down to the desired level. The method comprised two
stages. First, health spending was distributed according to the
different types of health care: hospital care, primary care, drugs,
and others. Second, the spending for each type of care was dis-
tributed among the ICD-9-CM categories. The base unit varied
according to each level: admissions for hospital care, appoint-
ments for primary care, and consumption per therapeutic sub-
group for drug treatment. RESULTS: In the period 1980–2000
health spending was concentrated into three ICD-9 categories:
VII, VIII and IX (37.4% of spending in 1980 and 40.1% of
spending in 2000). In terms of their relative rankings, category
VII was second in 1980 (10.1%) but had moved into ﬁrst place
by the year 2000 (17.6%), showing one of the highest growth
rates for the period. Category VIII (diseases of the respiratory
system) was ranked ﬁrst in 1980 (17.6%) but had fallen to
second place by 2000 (13.2%). As regards the third category (IX:
diseases of the digestive system) its relative position hardly
varied: 9.7% in 1980 and 9.3% in 2000. The results also show
that although the internal composition of each category (per-
centage of each type of health care) may vary widely, few im-
portant variations were observed between 1980 and 2000.
CONCLUSIONS: The information provided may be of use to
health managers and planners and it also establishes reference
baselines for cost-of-illness studies of speciﬁc pathologies.
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OBJECTIVES: The article is transversal comparison expenditure
analysis for drugs of 23 economicly developed european coun-
tries that are members of OECD. The data are related to year
2003, ﬁnancial indicators are expressed in dollars. METHODS:
Drug expenses are analysed in relation with those variables: GDP
per 1 inhabitant, health care expenses per 1 inhabitant, number
of physicians in praxis per 1000 inhabitants, proportion of
inhabitants of the age 65 years or more. Among all the variables
medium strong to strong relation was observed, determination
index between drug expenditure per 1 inhabitant and actual
number of active physicians and proportion of inhabitants of the
age 65 years or more reached the value of 51%. RESULTS:
Average drug expenditure per 1 inhabitant of the given year were
343 dollars, absolute average year growth in the years period
1995–2003, 19,4 dollars. Propotional expenditure average of
health care from GDP reached in the year 2003 value of 8,32%,
expenditure proportion on drugs from GDP was 1,37% from
health care expenditure 16,9%. By cluster analysis signiﬁcant
relation between drug expenditure and number of general physi-
cians and elderly inhabitants was determined. CONCLUSION:
Lower drug expenditures have countries with lower economical
efﬁciency, but also economicly developed European countries
where systemic regulations are applied, directed towards main
activators affecting the drug’s consumption and price.
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Until the late 1980s, the German health care machine worked
well. Since then, it has been challenged the restructuring of the
health care system of the former East Germany, economic down-
turn and changing demographics. OBJECTIVES: To analyze the
reforms in ﬁnancing and reimbursement in the German health
care system over the past 15 years to guide health reforms 
elsewhere. METHODS: A policy and evaluation analysis was
applied to the literature on health ﬁnancing reforms in Germany
to understand the contexts of the measures and their effects. To
understand the impact of the policies, a scale was developed to
assess the trajectory of the health care system as a result of the
reforms based on the principles of solidarity and subsidiarity on
which the German health care system was built. RESULTS: Clas-
siﬁcation of 12 reimbursement and ﬁnancing measures indicates
a shift away from the status quo from the solidarity-subsidiarity
dyad towards either the solidarity-governmental interference or
Eigenverantwortung (personal responsibility)-subsidiarity dyad.
Unfortunately, despite their collective potential of far-reaching
impact and long-term success, deﬁcit in operating mechanism(s)
and inconsistencies have hindered the supply-side cost-
containment measures of the past 15 years. CONCLUSION: Just
as a change in the environment requires new tools to address
challenges faced by the system, so does the approach to insti-
tuting reforms call for rethinking. While in the politics of health
policy evolutionary reforms may make more sense than radical
reforms, beyond evolutionary reforms which have produced only
modest results the sustainability of the ﬁnancing of the system
calls for radical reforms.
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OBJECTIVES: Analysis of utilization of the right to sick leaves
of the beneﬁciaries of the Republic Health Insurance Insti-
tute(RHII) in the period from January to September 2005, lasting
more that 30 days, analysis of the reasons for sick leaves and
suggested measures for more efﬁcient control over the rights to
beneﬁts, upgrading of utilization and guaranteeing the rights,
providing equal rights to all beneﬁciaries,and abuse reduction.
METHODS: Statistic data processing by uniform statistic forms
containing data on all medical commissions, classiﬁcation of
groups of deseases according to the ICD-10. RESULTS: The total
number of beneﬁciaries with temporary work disability was
263,825, 50,316 were enabled, 213,509 were given extensions
and 28,387 beneﬁciaries were sent to DMC. The most common
reasons for sick leaves were: vascular deseases 12.73%, bones,
joints & muscles system 11.36%, mental and behaviour disor-
ders 10.85%, injuries—distorsions and fractures 9.05%, tumors
